Cargando…
Dose Response and Pharmacokinetics of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
Longitudinal nonlinear mixed effects modeling was used to characterize the dose–response profile of tofacitinib using data from a placebo-controlled dose-ranging study, where tofacitinib 2, 5, and 15 mg twice daily (b.i.d.) were evaluated for plaque psoriasis treatment. Bayesian estimation was appli...
Autores principales: | Tan, H, Gupta, P, Harness, J, Wolk, R, Chapel, S, Menter, A, Strober, B, Langley, RG, Krishnaswami, S, Papp, KA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674331/ http://dx.doi.org/10.1038/psp.2013.22 |
Ejemplares similares
-
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+ )T lymphocyte cytokine production
por: Migita, Kiyoshi, et al.
Publicado: (2011) -
CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes
por: Migita, Kiyoshi, et al.
Publicado: (2011) -
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
por: Meyer, Debra M, et al.
Publicado: (2010) -
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight
por: Hutmacher, MM, et al.
Publicado: (2017) -
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis
por: Chen, Yong, et al.
Publicado: (2017)